Skip to main content

Market Overview

Atreca Opens For Trade

Share:

Atreca, Inc. (NASDAQ: BCEL) shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17.

Atreca is a biopharma company that uses its platform to discover and develop antibody-based immunotherapies to treat a range of solid tumor types. Unlike the traditional oncology drug discovery approaches, Atreca uses human immune system to lead it to unique antibody-target pairs from patients experiencing a clinically meaningful active immune response against their tumors.

The company's lead product candidate ATRC-101 is a monoclonal antibody, which reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical models.

Atreca generated a loss of $37.94 million in fiscal year 2018, wider than the loss of $27.53 million in the year-ago period. For the third quarter ended March 2019, the loss was $13.58 million.

The stock traded around $16.61 per share at time of publication.

Related Links:

Atreca IPO: What You Need To Know

FDA Approves Edesa's Dermatitis Treatment Study, Shares Up More Than 100%

 

Related Articles (BCEL)

View Comments and Join the Discussion!

Posted-In: News IPOs

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com